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We thank Dr. Rautou et al. for their interest in our Snapshot
review (in which we sought to summarize the important role that
platelets play in mediating coagulation and thrombosis in
patients with cirrhosis) [1]. We proposed that microparticles
could have important effects on coagulation and thrombosis in
these clinical settings. We mentioned the possibility of circulat-
ing cell-derived, and by inference (given the current state of the
ﬁeld), platelet microparticles as possible mediators of inﬂamma-
tion. Rautou and colleagues correctly point out that they and
other groups have recently published data in this area [2]. In
acute and chronic liver diseases, circulating microparticle levels
have consistently been shown to be increased, albeit previous
studies have shown variable levels of platelet-derived micropar-
ticles in these settings [3–7]. Importantly, Rautou et al. also found
that ‘‘the severity of cirrhosis and systemic inﬂammation were major
determinants of the levels of leuko-endothelial and hepatocyte
microparticles’’ [2]. Speciﬁcally, after correcting for the circulating
concentrations of platelets, the levels of platelet-derived micro-
particles in this study are lower in cirrhotic patients when com-
pared to controls [2]. Other investigators have suggested
increased levels of platelet microparticles in cirrhosis [3] or that
no differences are associated with increasing levels of hepatic
ﬁbrosis [6].
The origins of circulating microparticles, whether platelet-
derived or not, remain a point of contention. In truth, this is a
ﬁeld in evolution where critical elements of methodology are
yet to be determined. For example, Rautou et al. and other groups
have measured static microparticle levels. It is not clear if such
static values are pathophysiologically relevant, in relation to a
given stimulus, or whether the rapidity of changes in concentra-
tion levels and ﬂuxes over time are more important [5]. Nor is it
clear whether determination of CD41 labeling is sufﬁcient to
describe platelet versus megakaryocyte-derived microparticles
– in either health or disease states [8–10]. While Rautou et al. uti-
lize CD41 as a marker of platelet microparticles, the article that
we had cited utilized the related marker CD61 to measure plate-
let microparticles and infer that these may vary with inﬂamma-
tory insults as during and after an alcoholic binge [3].
Finally, Rautou et al. suggest tissue factor expressing micro-
particles may be more relevant as prothrombotic mediators in
liver disease and not platelet microparticles per se. Tissue factor
expression, typically thought to be distinct from platelet-derived
microparticles, can be readily found co-expressed with CD41 in
plasma microparticles using whole blood analyses and modiﬁed
techniques [8]. Clearly, microparticles can co-express a variety
of surface proteins (e.g., CD39), likely with unique biologica
properties depending on both source and target interaction
[11]. Further, one might speculate that microparticles from plate-
lets and other cellular sources could function as transport and
delivery systems for bioactive molecules in vivo, participating
not only in hemostasis and thrombosis but also in inﬂammation
angiogenesis, tissue remodeling, and cellular transformation [11]
As this ﬁeld matures and more data is available, the contro-
versies that uncertainty brings will likely settle. Future studiesJournal of Hepatology 201are needed to understand the respective roles of static/dynamic
changes in concentrations, to standardize methodology for the
quantiﬁcation process and to delineate not only the absolute lev-
els but also, importantly, any qualitative differences in micropar-
ticle populations.
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